3150 NW 107th Avenue, Miami FL 33172

Tel: 305.599.7174 Fax: 305.592.4621

K113477

510(k) Summary - NIPRO Huber Infusion Set

(21 CFR 807.92)

OCT 1 8 2012

1. Submitter:

Nipro Medical Corporation

FDA Registration No: 1056186

Contact Person:

Jessica Oswald

Prepared on:

21 November 2011

2. Trade Name:

NIPRO Huber Infusion Set

Common Name:

Huber Infusion Set

Classification Name:

Intravascular Administration Set

Classification Code:

FPA (per 21 CFR 880.5440)

Class II

3. Predicate Device:

NIPRO Huber Infusion Set (K895770)

4. Device Description:

The Nipro Huber Infusion Set is a standard non-coring Huber type needle and administration set. The device is designed for use with a vascular access infusion system and is intended for use as an intravascular administration set to access surgically implanted subcutaneous vascular ports in a standard manner for the purposes of fluid or drug infusion and blood sampling.

5. Indication for Use:

This device is intended for administration of drug solution, or blood sampling into/from a Reservoir implanted in the body.

6. Technological Characteristics

The basic structure of the device consists of a cannula, fixing rotating wings, a clamp, tube and luer connector. This device is also available with Y- tube and a injection plug. The needle is bent at a 90° angle and is available in gauges 19, 20 and 22 and in lengths of $\frac{1}{2}$ ".

7. Performance Testing

Testing of the NIPRO Huber Needle Infusion Set was completed in conformance with the following standards:

Reference Number	Infusion equipment for medical use Report
ISO 8536-4:2010	Infusion equipment for medical use, Part 4: Infusion sets for single use, gravity feed
ISO 10555-3:1996	Sterile single use catheters, Part 3: central venous catheters
ISO 7864:1993	Sterile hypodermic needles for single use
ISO 594-1:1986	Conical fittings with a 6% (Luer) taper for syringes, needles and certain other medical equipment – Part 1:General requirements
ISO 11135-1:2007	Sterilization of health care products – Ethylene oxide – Part 1: Requirements for the development, validation, and routine control of a sterilization process for medical devices.
ISO 10993-5:2009	Biological Evaluation of Medical Devices – Test for In Vitro Cytotoxicity
ISO 10993-4:2002	Biological Evaluation of Medical Devices – Selection of Test for Interaction with Blood
ISO 10993-10:2002	Biological Evaluation of Medical Devices – Test for Irritation and Delayed-Type Hypersensitivity
ISO 10993-11:2006	Biological Evaluation of Medical Devices – Test for Systemic Toxicity
IAEA-TECDOC-539	Guidelines for Industrial Radiation Sterilization of Disposable Medical Products (Cobalt-60 Gamma Irradiation)
USP 31	<151> Pyrogen Test (USP Rabbit Test)
JSP 31	<161> Transfusion and Infusion Assemblies and Similar Medical Devices
IS T3221:2005	Single-use needle for infusion port
P15	The Japanese Pharmacopoeia, Fifteenth Edition
ASTM D4169-05	Standard Practice for Performing Testing of Shipping Containers and Systems

NIPRO SafeTouch Huber Infusion Set successfully met the requirements for these standards. In addition, it met or exceeded the acceptance criteria for the following performance tests:

Acceptance Criteria	
19G: 41-52 ml/min	
20G: 24-38 ml/min	
22G: 10-15 ml/min	
24G: 4-6 ml/min	
Predicate Device 20G	
Must show no signs of air leakage of 50 [kPa] for 15 seconds.	
With y-site: 1.8MPa Without y-site: 3.7MPa	

Performance Test Name	Acceptance Criteria	
4. Wrapping paper leakage	Must not leak under the condition of 1.1[kPa] for 10 seconds.	
	19G: ≥ 69 N	
5. Cannula/Hub adhesive strength	20G: ≥ 54 N	
measurement	22G: ≥ 34 N	
•	24G: ≥ 22 N	
6. Popping needle tip inspection	No sound of puncture popping noise.	
7. Tensile Adhesive strength a. Hub / tube b. Y connector / tube c. Y connector / tube d. Connecting tube / connector	Must withstand a static tensile force of 15[N] for 15 seconds.	
8. Test for particulate matter	Contamination Index = Na - Nb 90	
9. Injection Site (rubber button)	Must show no signs of air leakage of 50 [kPa] for 15 seconds.	
10. Transportation Testing	Withstand distribution environment	

8. Substantial Equivalence

The Nipro Huber Infusion Sets are identical in physical properties, materials, configurations and having the same intended use as the predicate device (i.e., the original Exel Huber Infusion Set [K895770]). Although the manufacturing process for the needle bevel has been modified, performance testing shows that the performance of the new Nipro Huber Infusion Sets is similar in most performance test and is significantly better in the Coring Test. Therefore, no new issues of safety or effectiveness are introduced by these changes.

Specification	Nipro Hube	r Infusion Sets	Pre Exel Hube	dicate	
Physical and Mate	rial		* * * * * Exelinube	r intusion Set	
Needle	Components	Materials	Components	Materials	
	Cannula	Stainless Steel	Cannula	Stainless Steel	
	Protector	PVC	Protector	PC	
Wing Unit	AVF Rotary Hub	PVC	AVF Rotary Hub	PVC	
	AVF Rotary Wing	PE	AVF Rotary Wing	PE	
	Joint Tube	PVC	Joint Tube	PVC	
Tube	Tube	PVC	Tube	PVC	
	Y Tube	PC	Y Tube	PC	
Connector	Rubber Button	1R	Rubber Button	1R	
	Rubber Button Cap	PVC	Rubber Button Cap	PVC	
	Mini Clamp C	РОМ	Mini Clamp C	РОМ	
	Luer Connector	PC	Luer Connector	PC	
	Leur Cap	PP	Leur Cap	PP	
Bond		Epoxide-based adhesive		Epoxide-based adhesive	
	Urethane-based adhesive		Urethane-based adhesive		
Lubricants	Silicone oil		Silicone oil		
Available	Type A: Y-site with	Type A: Y-site with rubber button		Type A: Y-site with rubber button	
Configurations	Type B: Without Y-Site		Type B: Without Y-Site		
	Type C: Y-site with luer lock		Type C: Y-site with luer lock		
Mechanical					
Instructions for Use	Same		Same		
Operational					
Device Type	Standard non-coring Huber needle		Same		
Biological	Biocompatibility tests were performed according to ISO 10993 Parts 4, 5, 10 and 11 as a prolonged duration, indirect blood path contacting device.		Same		
Sterilization Method	Ethylene oxide		Same		

PVC:polyvinyl chloride PE:polyethylene PP:polypropylene POM: polyoxymethylene PC:polycarbonate IR:isoprene rubber PEI: polyetherimide







Food and Drug Administration 10903 New Hampshire Avenue Document Control Room --WO66-G609 Silver Spring, MD 20993-0002

OCT 1 8 2012

Nipro Medical Corporation Ms. Jessica Oswald-McLeod Regulatory Affairs 3150 North West 107TH Avenue Miami, Florida 33172

Re: K113471

Trade/Device Name: Nipro Huber Infusion Set, Excel Huber Infusion Set

Regulation Number: 21 CFR 880.5440

Regulation Name: Intravascular Administration Set

Regulatory Class: II Product Code: FPA Dated: October 10, 2012 Received: October 11, 2012

Dear Ms. Oswald-McLeod:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to

http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Anthony D. Watson, B.S., M.S., M.B.A.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K113471

Device Name: NIPRO Huber Infusion Set /EXEL Huber Infusion Set	
Indications for Use:	
This device is intended for administration of drug solution, or blood sampling into/from a Reservoir implanted in the body.	
Prescription Use X Over-The-Counter Use (Part 21 CFR 801 Subpart D) AND/OR (21 CFR 801 Subpart C)	
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)	F
· · · · · · · · · · · · · · · · · · ·	
Concurrence of CDRH, Office of Device Evaluation (ODE)	
Di Ch 10/17/1	
(Division Sign-Off) (Division of Anesthesiology, General Hospital Division Control, Dental Devices	ı
(Division of Anesthesiology Division of Anesthesiology Division Control, Dental Devices	
mbor: CII	